Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale?

被引：178

作者：

Rosh, Joel R. ^{[1
]}

Gross, Thomas

Mamulo, Petar

Griffiths, Anne

Hyams, Jeffrey

机构：

[1] Goryeb Childrens Hosp Atlantic Hlth, Morristown, NJ 07962 USA

[2] Columbus Childrens Hosp, Columbus, OH USA

[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[4] Toronto Sick Childrens Hosp, Toronto, ON, Canada

[5] Connecticut Childrens Med Ctr, Hartford, CT USA

来源：

INFLAMMATORY BOWEL DISEASES | 2007年 / 13卷 / 08期

关键词：

infliximab; lymphoma; thiopurines; Crohn's disease; pediatrics;

D O I：

10.1002/ibd.20169

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Therapy for the inflammatory bowel diseases increasingly includes the use of immune-modifying and biologic therapies. Recently, in young patients with IBD, an association has been noted between the use of infliximab along with concomitant purine analogues and the development of hepatosplenic T-cell lymphoma (HSTCL)-a rare and all but incurable form of non-Hodgkin's lymphoma. This report briefly reviews the issue of lymphoma and IBD therapy. Additionally, a description of HSTCL and a summary of the known cases of this apparent therapeutic complication are presented. Clinical options in light of this new information are explored.

引用

页码：1024 / 1030

页数：7

共 53 条

[1] Natalizumab and progressive multifocal leukoencephalopathy [J].

Adelman, B ;

Sandrock, A ;

Panzara, MA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) :432-433

[2]

[Anonymous], 1999, Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995

[3]

ARMITAGE JO, 2004, NONHODGKINS LYMPHOMA, P405

[4] The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients [J].

Arseneau, KO ;

Stukenborg, GJ ;

Connors, AF ;

Cominelli, F .

INFLAMMATORY BOWEL DISEASES, 2001, 7 (02) :106-112

[5] Risk of haematopoietic cancer in patients with inflammatory bowel disease [J].

Askling, J ;

Brandt, L ;

Lapidus, A ;

Karlén, P ;

Björkholm, M ;

Löfberg, R ;

Ekbom, A .

GUT, 2005, 54 (05) :617-622

[6] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[7] Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome:: report on a series of 21 patients [J].

Belhadj, K ;

Reyes, F ;

Farcet, JP ;

Tilly, H ;

Bastard, C ;

Angonin, R ;

Deconinck, E ;

Charlotte, F ;

Leblond, V ;

Labouyrie, E ;

Lederlin, P ;

Emile, JF ;

Delmas-Marsalet, A ;

Arnulf, B ;

Zafrani, ES ;

Gaulard, P .

BLOOD, 2003, 102 (13) :4261-4269

[8]

Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO

[9]

2-Z

[10] Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study [J].

Biancone, L ;

Orlando, A ;

Kohn, A ;

Colombo, E ;

Sostegni, R ;

Angelucci, E ;

Rizzello, F ;

Castiglione, F ;

Benazzato, L ;

Papi, C ;

Meucci, G ;

Riegler, G ;

Petruzziello, C ;

Mocciaro, F ;

Geremia, A ;

Calabrese, E ;

Cottone, M ;

Pallone, F .

GUT, 2006, 55 (02) :228-233

← 1 2 3 4 5 6 →